Product and Pipeline Analysis of the Global Parkinson's Disease Therapeutics Market
Product and Pipeline Analysis of the Global Parkinson's Disease Therapeutics Market
RELEASE DATE
04-Feb-2014
04-Feb-2014
REGION
North America
North America
Research Code: MA14-01-00-00-00
SKU: LS00099-NA-MR_16940
$3,950.00
Special Price $2,962.50 save 25 %
In stock
SKU
LS00099-NA-MR_16940
Description
This research service focuses on existing therapeutics and product pipeline for the treatment of Parkinson’s Disease using Dopamine Replacement Therapies, Dopamine Agonists, MAO-inhibitors, COMT-inhibitors and other pharamcolgical approaches for current global interest. This research service does not cover vaccines. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for Parkinson’s Disease therapeutics. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.
Table of Contents
Executive Summary
Recent Market Developments
Companies to Watch
Key Trends in Parkinson’s Disease Therapeutics
Methodology and Scope
Introduction
Global Prevalence of Parkinson’s Disease by Country
Global Incidence of Parkinson’s Disease by Country
Market Overview—Segmentation by Types of Therapeutics
Market Overview—Segmentation Illustrated
Market Overview—Segmentation Illustrated (continued)
Overview of Market Opportunities
Competitive Landscape—Marketed Products and Products in Development
Marketed Product Synopsis—Parkinson’s Disease Therapeutics
Marketed Product Synopsis—Parkinson’s Disease Therapeutics (continued)
Marketed Product Synopsis—Parkinson’s Disease Therapeutics (continued)
Marketed Product Synopsis—Parkinson’s Disease Therapeutics (continued)
Pipeline Synopsis—Parkinson’s Disease Therapeutics
Pipeline Synopsis—Parkinson’s Disease Therapeutics- Continued
Pipeline Synopsis—Parkinson’s Disease Therapeutics- Continued
Pipeline Synopsis—Parkinson’s Disease Therapeutics- Continued
Parkinson’s Disease Therapeutics Market—Competitive Landscape: Major Ongoing Trials
Competitive Landscape—Projected Launch Timeline for Key Pipeline Drugs
Competitive Landscape—Company Assets by Drug Pipeline Class
Key Marketed Products Dashboard: Stalevo (Carbidopa-Levodopa-Entacapone)—Orion Corporation
Key Marketed Products Dashboard: Sinemet (carbidopa-levodopa)—Merck & Co
Key Marketed Products Dashboard: Azilect (Rasagiline) By TEVA Pharmaceuticals
Key Marketed Products Dashboard: Zelapar (Selagiline) By Valeant Pharmaceuticals
Key Marketed Products Dashboard: Mirapex (Pramipexole) By Boehringer Ingelheim
Key Marketed Products Dashboard: Neupro (Rotigotine) By UCB Inc. and Schwarz Pharma
Key Marketed Products Dashboard: Requip (Ropinirole) By Glaxo SmithKline
Key Phase 3 Products Dashboard:Nouriast® (Istradefylline) By Kyowa Hakko Kirin
Key Phase 2 Products Dashboard:Ampyra® (dalfampridine) By Acorda Therapeutics
Key Phase 3 Products Dashboard:Duodopa® (sinemet) By AbbVie Pharmaceutical
Conclusion
Conclusions (Continued)
Legal Disclaimer
Decision Support Database—Global Population with Parkinson’s Disease
Decision Support Database—Global Population with Parkinson’s Disease (continued)
Who is Frost & Sullivan
What Makes Us Unique
TEAM Methodology
Our Global Footprint 40+ Offices
Popular Topics
This market insight provides data for the global multiple sclerosis (MS) market. The analysis looks at MS pharmaceutical pipeline drugs that are currently in the market as well as any drugs that are in Phase III trials and pose a potential threat to competitors. It offers a competitive analysis of these drugs and the forecasted outcome and impact of each of these drugs. Injectable drugs dominate MS drugs currently in the market, but the launch of numerous oral pipeline products can shift this market in favor of oral drugs. The MS market is segmented into relapsing, remitting, secondary progressive, primary progressive, and progressive relapsing MS drugs.
No Index | No |
---|---|
Podcast | No |
WIP Number | MA14-01-00-00-00 |
Is Prebook | No |